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Introduction: Altered expression of MUC4 plays an oncogenic role 
in various cancers, including pancreatic, ovarian, and breast. This 
study evaluates the expression and role of MUC4 in non–small-cell 
lung cancer (NSCLC).
Methods: We used a paired system of MUC4-expressing (H292) and 
MUC4-nonexpressing (A549) NSCLC cell lines to analyze MUC4-
dependent changes in growth rate, migration, and invasion using 
these sublines. We also evaluated the alterations of several tumor 
suppressor, proliferation, and metastasis markers with altered MUC4 
expression. Furthermore, the association of MUC4 expression (by 
immunohistochemistry) in lung cancer samples with patient survival 
was evaluated.
Results: MUC4-expressing lung cancer cells demonstrated a less 
proliferative and metastatic phenotype. Up-regulation of p53 in 
MUC4-expressing lung cancer cells led to the accumulation of cells 
at the G2/M phase of cell cycle progression. MUC4 expression 
attenuated Akt activation and decreased the expression of Cyclins 
D1 and E, but increased the expression of p21 and p27. MUC4 
expression abrogated cancer cell migration and invasion by altering 
N- & E-cadherin expression and FAK phosphorylation. A decrease in 
MUC4 expression was observed with increasing tumor stage (mean 
composite score: stage I, 2.4; stage II, 1.8; stage III, 1.4; and meta-
static, 1.2; p = 0.0093). Maximal MUC4 expression was associated 
with a better overall survival (p = 0.042).
Conclusion: MUC4 plays a tumor-suppressor role in NSCLC by 
altering p53 expression in NSCLC. Decrease in MUC4 expression 
in advanced tumor stages also seems to confirm the novel protective 
function of MUC4 in NSCLC.
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(J Thorac Oncol. 2013;8: 398-407)
MUC4 (mucin 4) is a high–molecular-weight type-I transmembrane protein. The canonical MUC4, i.e., the 
longest isoform, is expressed as a single propeptide that is 
predicted to undergo cleavage and dimerization. The result-
ing mucin-like subunit MUC4α with an N-terminal domain, 
unique 16-mer tandem repeat (TR) domain of variable length, 
a nidogen-like (NIDO) domain, and an adhesion-associated 
domain (AMOP) dimerizes with the growth factor–like 
subunit MUC4α carrying von-Willebrand factor and three 
epidermal growth factor and epidermal growth factor–like 
domains and anchors to the cell membrane with a 21-mer 
transmembrane domain of MUC4β.1 In addition, MUC4β car-
ries a short (22-mer) cytoplasmic tail. The MUC4 TR domain 
is rich in proline, threonine, and serine residues and is a target 
for O-linked glycosylation, which could amount to 50% of the 
total molecular weight of MUC4.
MUC4 is expressed by the epithelia of the tubular 
organs such as lung,2 colon,3 cervix,4 cornea,5 prostate,6 
middle ear, and Eustachian tube.7 However, the functional 
role of MUC4 has been best studied in malignancies of organs 
that normally lack MUC4 expression including pancreas,8 
ovary,9 and breast.10 In pancreatic cancer, a novel gain of 
function due to aberrant overexpression and/or loss of cell 
polarity enabling MUC4 to physically interact with, activate 
(by phosphorylation), and stabilize HER2, a ligand-dependent 
receptor tyrosine kinase, seems to be the principal mechanism 
of MUC4-associated pathogenesis.1,11
MUC4 expression is observed at all levels in the respi-
ratory tract, i.e., trachea, main bronchus, lobar bronchus, 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0804-0398
Pathobiological Implications of MUC4 in  
Non–Small-Cell Lung Cancer
Prabin Dhangada Majhi*, Imayavaramban Lakshmanan*, Moorthy P. Ponnusamy*, Maneesh Jain*, 
Srustidhar Das*, Sukhwinder Kaur*, Su Tomohiro Shimizu*, William W. West†, Sonny L. Johansson†,‡, 
Lynette M. Smith§, Fang Yu‖, Cleo E. Rolle¶, Poonam Sharma#, George B. Carey¶, Surinder K. Batra*,‡, 
and Apar Kishor Ganti**††
*Department of Biochemistry and Molecular Biology, University of 
Nebraska Medical Center, Omaha, NE; †Department of Pathology and 
Microbiology, University of Nebraska Medical Center, Omaha, NE; 
‡Eppley Institute for Research in Cancer and Allied Diseases, University 
of Nebraska Medical Center, Omaha, NE; §Center for Collaboration on 
Research, Design and Analysis, College of Public Health, University 
of Nebraska Medical Center, Omaha, NE; ‖Department of Biostatistics 
College of Public Health, University of Nebraska Medical Center, 
Omaha, NE; ¶Section of Hematology-Oncology Department of Medicine, 
University of Chicago, Chicago, IL; #Department of Pathology and 
Creighton Medical Laboratories, Creighton University Medical Center, 
Omaha, NE; **Department of Internal Medicine, VA Nebraska-Western 
Iowa Health Care System, Omaha, NE; ††Division of Oncology-
Hematology, Department of Internal Medicine, University of Nebraska 
Medical Center, Omaha, NE.
Prabin Dhangada Majhi and Imayavaramban Lakshmanan contributed 
equally to this article
Disclosure: This work is supported by a grant from the US Department of 
Veteran Affairs.
Address for correspondence: Apar Kishor Ganti, MD, MS, FACP, Division of 
Oncology-Hematology, Department of Internal Medicine, University of 
Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 
68198-7680. E-mail: aganti@unmc.edu
ORIGINAL ARTICLE
399Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013 MUC4 Attenuates Tumorigenicity in NSCLC
smaller bronchi, and bronchioles, but is undetectable in 
submucosal glands and alveolar epithelial cells.12 MUC4 
is highly expressed in the surface epithelium lining, i.e., in 
ciliated cells, goblet cells, and basal cells.13 MUC4 expres-
sion was found to be associated with precancerous lesions 
like squamous cell metaplasia, dysplasia, and also with well-
differentiated squamous cell carcinoma.14 However, MUC4 
expression in neoplastic lung seems to vary based on histo-
logic subtypes. Among the non–small-cell lung carcinomas 
(NSCLC), MUC4 expression was more characteristic of 
adenocarcinoma than squamous cell carcinoma.15 Clinically, 
MUC4 expression in small lung tumors was found to cor-
relate with shorter disease-free survival and poor survival.16 
However, in another study, an increase in MUC4 immunore-
activity was found to be associated with a longer patient sur-
vival.15 Given these discrepancies in the literature, we have 
investigated the role and mechanism of MUC4 in lung cancer 
progression.
PATIENTS AND METHODS
The study was approved by the Institutional Review 
Board and other regulatory committees at the VA Nebraska-
Western Iowa Health Care System.
Cell Culture and Transfection
Human NSCLC cell lines NCI-H292 and A549 were 
purchased from the American Type Culture Collection 
(Manassas, VA). Stable clones of NCI-H292 in which MUC4 
was down-regulated using small-hairpin RNA against target 
sequence (5′-CAGCGACACTAGAGGGACA-3′) located 
151 bp downstream of ATG (H292-ShMUC4) and scramble 
transfected control sublines expressing endogenous MUC4 
(H292-Scr) were established as described previously.17 Stable 
clones of mini-MUC4 transfected A549 (A549-MUC4) 
overexpressing an estimated 320 kDa MUC4 protein con-
taining all domains of wild-type MUC4 but only 10% of the 
TRs and empty vector control (A549-PsecTagC) were estab-
lished as described earlier.18 NCI-H292 cells were routinely 
grown in RPMI-1649 medium (Sigma-Aldrich, St. Louis, 
MO) supplemented with 10% complement-inactivated fetal 
bovine serum (FBS), 100 units of penicillin, and 100 µg/ml 
streptomycin. A549 cells were grown in F12K media sup-
plemented with 15% FBS, 100 units of penicillin, and 100 
µg/ml of streptomycin. Media of transfected cell lines were 
supplemented with either 1 µg/ml puromycin (NCI-H292) or 
200 µl/ml zeocine (A549).
Proliferation Assay
For growth curve analyses, cells were seeded in six-
well plates at a density of 1 × 103 cells/well. After 24 hours of 
growth, media were changed to 1% FBS in RPMI (H292-Scr 
and H292-ShMUC4) and 5% FBS in F12K (A549-Vector and 
A549-MUC4). Viable cell numbers from triplicate wells were 
determined every 24 hours for 6 days by trypan blue exclusion 
using a Vi-Cell XR instrument (Beckman Coulter, Fullerton, 
CA). For cell cycle analyses, 1 × 106 cells were grown briefly 
in 10-mm plates and synchronized with 2 mM thymidine for 
12 hours, followed by treatment with 2-deoxycytidine 9 hours 
and a second 2 mM thymidine block for 14 hours. Cells were 
released in complete media for 48 hours, collected, fixed in 
70% ethanol, and stained with Telford reagent (90 mM ethyl-
enediaminetetraacetic acid, 2.5 mU of RNase A/ml, 50 mg of 
propidium iodide/ml, and 0.1% Triton X-100 in phosphate-
buffered saline [PBS]). DNA content was then analyzed by 
fluorescence-activated cell sorting analyses.
Cell Motility Assay
In serum-free media, 1 × 106 cells/chamber were plated 
on the noncoated polyethelene terapthalate (PET) membrane 
chambers (8 µm, Becton Dickinson, Franklin Lakes, NJ), 
inserted into six-well plates containing 10% FBS in media, 
and grown for 24 hours. The PET inserts were washed and 
stained in Diff-Quick cell staining kit (Dade Berhing Inc., 
Newark, DE) and cells that did not migrate were scrapped 
off with cotton swabs. Cells that traversed and stained were 
counted in 10 random fields of view at 10× magnification, in 
a phase-contract microscope and expressed as number of cells 
per view. For the in vitro scratch assay, H292-Scr and H292-
ShMUC4 cells were grown at 6 × 106 in 10-cm cell plates. 
Cells were imaged at 0, 24, and 48 hours of growth. H292-Scr 
cells showed less migration than H292-ShMUC4 cells at cor-
responding time points.
Cell Invasion Assay
The invasive potential of the NSCLC cells was esti-
mated by their ability to penetrate PET membrane coated with 
a thin layer of Matrigel (BD Biocoat Matrigel six-well cell 
invasion chamber). For each experiment, 1 × 105 cells/well in 
2 ml of RPMI media (or F12K media) containing serum-free 
media were loaded onto the top chamber and 2 ml of complete 
RPMI media (F12K media) was added in the bottom cham-
ber. After 24 hours of incubation, invasive cells reaching the 
lower side of the PET membrane were stained and measured 
as described earlier.
Quantitative Real-Time Polymerase 
Chain Reaction Analyses
Total cellular RNA was isolated from cells grown 
in complete RPMI media for 48 hours using RNeasy kit 
(Qiagen, Valencia, CA), according to the manufacturer’s 
instruction. Total RNA was reverse-transcribed and quan-
titative real-time polymerase chain reaction was performed 
using SYBR Green method in a LightCycler 480 II (Roche, 
Basel, Switzerland).
Apoptosis Assay
Apoptosis was measured by Annexin-V-FLUOS staining 
kit (Roche diagnostics, Indianapolis, IN). Cells (1 × 106/10-
cm plate) were incubated overnight and grown in 1% serum 
for the next 48 hours. Cells were collected and stained with 
Annexin-V and propidium iodide solution, and the percentage 
of apoptotic and necrotic cells was measured by fluorescence-
activated cell sorting analyses.
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Immunoblot Analyses
Cells were typically grown for 48 hours in complete 
media, unless mentioned otherwise, and total protein lysate 
was collected in RIPA lysis buffer (50 mM Tris–Cl, pH 7.4; 
150 mM NaCl; 1% Nonidet P-40; 0.25% Na-deoxycholate; 
1 mM ethylenediaminetetraacetic acid; 1 mM phenylmeth-
ylsulfonyl fluoride; 1 µg/ml aprotinin and leupeptin; 1 mM 
Na
3
VO
4
; and 1 mM NaF) and passed through a 25-gauge 
syringe several times. Total protein content was assayed 
with the Bio-Rad D
C
 Protein assay (Bio-Rad, Hercules, CA). 
Protein lysates (40 µg/ml) were loaded onto a sodium dodecyl 
sulfate–agarose gel (2%) under reduced conditions to resolve 
and immunoblot for MUC4. All other proteins were resolved 
in sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis (10%). Resolved proteins were transferred to polyvinyli-
dene difluoride membrane and blocked in nonfat milk (5%) 
for 1 hour. The membrane was incubated in the appropriate 
primary antibody according to the manufacturer’s instructions 
for MUC4 at 1 µg/ml in PBS for 2 hours at room tempera-
ture, followed by 4 × 10 minute washes in Tris-buffered saline 
Tween-20 (50 mM Tris–Cl, pH 7.4; 150 mM NaCl, and 0.05% 
Tween-20). The membrane was incubated for 1 hour with the 
appropriate secondary antibody conjugated with horseradish 
peroxides at the dilution of 1:2000 in PBS, followed by 4 × 10 
minute washes in Tris-buffered saline Tween-20. Enhanced 
chemiluminiscence reagents (Amersham Biosciences, 
Piscataway, NJ) were applied on the membrane as per the 
manufacturer’s instructions, and the blot was exposed to an 
ECL-sensitive film (Biomax Films, Kodak, Rochester, NY).
Tissue Microarrays and Immunohistochemistry
A lung cancer tissue microarray (TMA) was obtained 
from US Biomax, Inc. (Rockville, MD) The TMA (Cat. No. 
BC0402) has a total of 100 tissues from a spectrum of malig-
nant, nonmalignant lung diseases, and normal lung, including 
20 cases each of squamous cell carcinoma and adenocarci-
noma of varying grades, 10 cases each of small cell undif-
ferentiated carcinoma, alveolar cell carcinoma, and metastatic 
squamous cell carcinoma, and 5 cases each of carcinoid, 
inflammatory pseudotumor, tuberculosis, cancer adjacent tis-
sue, cancer adjacent normal tissue, and normal lung tissue. 
In addition, samples were obtained from patients with stages 
I–III NSCLC from the University of Chicago specimen bank 
(Courtesy: Dr. Ravi Salgia). MUC4 expression was correlated 
with tumor stage and survival. In addition, where paired sam-
ples were available from the tumor and corresponding lymph 
node, MUC4 expression between the two was compared.
As per recommendations of the manufacturer, before 
immunohistochemistry, the slides were baked at 60°C for 2 
hours. Then, slides were deparaffinized using EzDewax (Bio 
Genex, Fremont, CA) for 30 minutes. Sections were hydrated 
through graded alcohol and endogenous peroxidase activity 
was quenched by incubating the sections in 0.3% H
2
O
2
 in meth-
anol for 30 minutes. After washing the slides in PBS (5 min-
utes × 2), antigen was retrieved by heating the slides in citrate 
buffer (0.01 M, pH 6.0) at 80°C for 20 minutes. After heating, 
the samples were allowed to cool for 15–20 minutes in room 
temperature, followed by washing with PBS (5 minutes × 2). 
Nonspecific binding was blocked by incubating the sections with 
2.5% horse serum for 30 minutes (Impress reagent Kit, Vector, 
CA). This was followed by washing with PBS (5 minutes × 2). 
Sections were then incubated with anti-MUC4 monoclonal 
antibody (1:500) at 4°C overnight. The slides were washed 
and incubated with secondary antibody (peroxidase-labeled 
Universal antimouse/antirabbit IgG) (Vector, Burlingame, CA) 
for 30 minutes. Sections were then washed with PBS followed 
by treatment with diamino benzidine reagents (0.2 mg/ml) and 
incubated for 10 minutes. After washing with distilled water, 
counterstaining was done by using hematoxylin (Vector). After 
washing in tap water, sections were dehydrated in graded alco-
hol, and after air drying, the slides were mounted in Permount 
permanent mounting media (Fisher Scientific, Fair Lawn, NJ). 
All slides were observed under Nikon E400 light microscope 
and representative photographs were taken.
Statistical Analyses
All experiments were performed in triplicates, and 
the statistical significance of the results was analyzed using 
Student’s t test or Mann–Whitney test. For patient samples, 
Mann–Whitney test was used to compare composite score 
between groups. For paired comparison of composite score 
between metastatic and primary tumor, the Wilcoxon signed 
rank test was used. Chi-square tests were conducted for cat-
egorical data. Overall survival is defined as time from diag-
nosis to death or last follow-up. The Kaplan–Meier method 
was used to estimate overall survival distributions and the log-
rank test was used to compare survival distributions between 
groups. Pair-wise p values were adjusted for multiple com-
parisons with Bonferroni’s method. A p value of less than 0.05 
was considered to be statistically significant.
RESULTS
MUC4 Expression in Lung Cancer
To investigate the causal relationship of MUC4 down-reg-
ulation with tumor progression in vitro, a panel of eight NSCLC 
lung cell lines was screened for MUC4 expression, of which 
H292 and HCC827 cell lines showed high level of expression by 
quantitative real-time polymerase chain reaction (Fig. 1A). MUC4 
expression was silenced in H292 by retroviral RNAi method as 
described previously.1 Stable ectopic expression of the MUC4 
gene containing all unique domains of MUC4 along with 10% of 
the TR was obtained by transfection in a MUC4-nonexpressing 
cell line A549. Knockdown of endogenously expressed MUC4 
in H292 and the ectopic expression of MUC4 in A549 were con-
firmed by Western blot and confocal analysis (Fig. 1B).
MUC4 Attenuates In Vitro 
Proliferation of NSCLC Cells
Growth rates of H292-ShMUC4 and A549-MUC4 cells 
were compared with those of control H292-Scr and A549-
Vector, respectively. MUC4 knockdown H292 cells showed a 
significantly increased cell growth rate compared with control 
cells (p = 0.011) (Fig. 2A). Similarly, MUC4-expressing 
A549-MUC4 cells showed significantly decreased cell growth 
compared with control A549-Vector cells (p = 0.053) (Fig. 2B). 
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Decreased growth rates in the presence of MUC4 could result 
either from an impairment of cell cycle progression or an 
increase in cell death. Cell cycle analyses after synchronization 
with double-thymidine block showed a higher percentage of 
cells in S-phase in H292-ShMUC4 cells (Fig. 2C) as compared 
with H292-Scr cells (p = 0.034). Similarly, A549-PsecTagC 
cells showed increased S-phase population (Fig. 2D) compared 
with A549-MUC4. These results suggest that expression of 
MUC4 suppresses lung cancer cell growth.
MUC4 Abrogates Proliferative 
Signals in Lung Cancer
Previous studies on MUC4 in different cancers have 
shown that MUC4 interacts with and stabilizes HER2, which 
mediates downstream proliferative signals such as activation 
of PI3K/Akt and MEK/Erk pathway.1 Because our studies 
imply an opposite function of MUC4 in NSCLC, we hypoth-
esized that MUC4 plays a tumor-suppressor role in lung 
cancer. In contrast to the previous study, pY1248HER2 and 
total HER2 levels were unaffected (Fig. 3A). However, with 
MUC4 down-regulation, a significant increase in phosphor-
ylation of Akt (Ser473) was observed while total Akt level 
was unchanged (Fig. 3B). Activated Akt phosphorylates mul-
tiple downstream targets to stimulate cell proliferation. These 
functions include phosphorylation and proteasomal targeting 
of p21Cip1 and p27Kip1, and inactivation of GSK3β that stabi-
lizes G1 cyclins (Cyclin D and E) and transcription factors 
c-Jun and c-Myc.19 We observed elevated levels of inactive 
pSer9-GSK3β and Cyclin D and A, and a decrease in p21Cip1 
and p27Kip1 in both MUC4 knockdown (H292-ShMUC4) and 
MUC4-nonexpressing (A549-Vector) cells, compared with 
their MUC4-expressing sublines (Fig. 3B).
In a previous study on the role of MUC4 in pancreatic 
cancer cell line CD18/HPAF, transcriptome analyses showed 
2.5-fold increases in TP53 after down-regulation of MUC4.17 
Results of our study show that p53 mRNA and protein were 
more drastically decreased in MUC4 knockdown H292 cells 
than in control cells, and conversely, MUC4 expression 
increased p53 level (Fig. 3B and C), suggesting that MUC4 
may transcriptionally regulate p53 expression.17 In addition, 
as a result of HER2/neu overexpression, Akt interacts and 
phosphorylates MDM2 and increases p53 degradation,20 sug-
gesting an opposite function of MUC4 in lung cancer com-
pared with pancreatic cancer. Moreover, based on this finding, 
we suggest that the interplay of MUC4 with p53 mediates the 
tumor-suppressor role of MUC4 in lung cancer. Expression of 
MUC4 attenuated the activation of Cyclins D1 and A, result-
ing in the decreased cancer cell proliferation compared with 
cells lacking MUC4 (Fig. 3B).
NSCLC Cell Migration and Invasion 
Properties are MUC4 Dependent
To determine if MUC4 affects cell migration, we 
performed a wound-healing assay. A scratch was made in 
H292-ShMUC4 or H292-Scr cells grown to 90% confluency 
on a 10-mm plate, and the migration of cells to the scratch 
wound was observed over time. We observed that H292-
ShMUC4 cells covered the scratch faster than the control 
(Fig. 4A). To corroborate this result, quantitative cellular 
motility assay was performed using Boyden chamber with 
PET membrane. H292-ShMUC4 and A549-Vector cells 
showed increased motility compared with H292-Scr (p = 
0.0047) and A549-MUC4 (p = 0.0036), respectively (Fig. 4B). 
Invasive properties of both NSCLC cell lines were estimated 
with in vitro invasion assay. H292-ShMUC4 and A549-Vector 
cells showed more cells traversing the Matrigel-coated PET 
membrane than cells expressing MUC4 (Fig. 4C).
To determine the cause of altered motility and invasive 
potential of MUC4-expressing lung cancer cells at the molec-
ular level, confocal and Western blot analyses for markers of 
epithelial (E-cadherin/CDH1 and CK-18) and mesenchymal 
(N-cadherin/CDH2) phenotype were performed. The results 
FIGURE 1.  Screening of MUC4 in lung cancer cell lines, 
knockdown of MUC4, and ectopic expression of mini-MUC4 
in lung cancer cells. (A) MUC4 expression was observed in 
H827 and H292 lung cancer cells by real-time polymerase 
chain reaction quantitative screening assay. (B) Stable knock-
down of MUC4 was carried out by shRNA method in H292 
cells (H292-ShMUC4) and control cells by scrambled shRNA 
(H292-Scr). MUC4 was also ectopically expressed in MUC4-
nonexpressing A549 lung cancer cells (A549-MUC4) and 
control cells transfected with empty vector (A549-PsecTagC). 
Western blot and confocal images show the range of MUC4 
knockdown in H292 and overexpression in A549 cells in com-
parison with control cells.
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FIGURE 2.  Effect of MUC4 on 
the growth NSCLC cells. Growth 
kinetics results show that MUC4 
knockdown H292 cells have 
higher proliferative activity in 
comparison with vector control 
cells (A). Similarly, A549-Vector 
cells have a higher growth rate 
compared with MUC4-transfected 
A549 cells (B). Cell cycle analy-
ses show that the percentage 
of S-phase cells is decreased in 
MUC4-expressing H292-Scr and 
A549-MUC4 cells compared with 
MUC4-negative H292-ShMUC4 
and A549-Vector, respectively. In 
addition, more MUC4-expressing 
(H292-Scr and A549-MUC4) cells 
were accumulated in the G2/M 
phase of cell cycle than MUC4-
absent (H292-ShMUC4 and A549-
Vector) cells.
FIGURE 3.  Altered MUC4 expression affects cell proliferative signals in H292 and A549 cell lines. (A) Western blot results show 
no changes in phosphorylation of HER2 in H292 cells. (B) Immunoblot analyses showing a decrease in phospho-Akt and down-
stream molecules Cyclin D1 and Cyclin A, and an increase in the expression of p53, p21Cip1, and p27Kip1 in the presence of 
MUC4 in both H292 and A549 cell lines at the (B) protein level and (C) transcript level.
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show that the distribution of the epithelial marker E-cadherin 
was drastically decreased, whereas mesenchymal marker 
N-cadherin expression was high in MUC4 knockdown cells 
(Fig. 5A, left panel). Similar results were observed in MUC4-
overexpressing A549 and A549-PsecTagC cells with the epi-
thelial marker CK-18 and N-cadherin (Fig. 5A, right panel). 
FIGURE 4.  Analyses of cell migration and invasion. (A) in vitro scratch assay: H292-Scr and H292-ShMUC4 cells were plated 
at 6 × 106 in 10-cm plates. Cells were imaged at 0, 24, and 48 hours of growth. (B and C) Boyden chamber motility assay and 
Matrigel-coated Boyden chamber invasion assay results show that MUC4-expressing H292-Scr and A549-MUC4 cells are less 
motile and invasive than H292-ShMUC4 and A549-Vector cells.
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Western blot results confirmed these findings (Fig. 5B). These 
results strongly suggest that MUC4-expressing lung cancer 
cells have less-invasive and motile properties because of the 
alteration of these markers.
Binding of β1 integrin to collagen ligand activates 
intracellular signaling such as phosphorylation of FAK and 
Src.21 Phosphorylation of FAK at Y925 and Y577 was high in 
MUC4 knockdown cells (high invasive and motile property) 
compared with control cells (Fig. 5C), suggesting that in the 
absence of MUC4, pFAK is activated and potentially mediates 
the metastasis of lung cancer. The total FAK, however, was 
unchanged (Fig. 5C).
MUC4 Expression Gradually Decreases 
with Increasing Stage of Malignancy
Owing to the contradictions in MUC4 expression and 
its correlation with tumor progression in the previous studies, 
we evaluated MUC4 expression in a commercially available 
lung cancer tissue array by immunohistochemistry. A total of 
100 tissue spots were examined comprising the cancer stages 
I (n = 29), II (n = 15), III (n = 21), and IV (n = 10) and non-
malignant lung tissues (n = 25). We detected least MUC4 
immunoreactivity in the nonmalignant specimens (mean com-
posite score: 0.08), whereas MUC4 immunoreactivity was 
found in all stages of cancer (Fig. 6). A gradual decrease in 
the expression was observed with the progression of disease 
(mean composite score: stage I, 2.4; stage II, 1.8; stage III, 
1.4; and metastatic, 1.2; p = 0.0093).
MUC4 Expression Is Associated 
with Improved Survival
An additional 167 samples from 54 nonmetastatic 
patients with NSCLC with available clinical data were ana-
lyzed for MUC4 expression. Of these, 13 patients (25%) had 
stage I, 33 patients (63%) had stage II, and six patients (12%) 
had stage III disease. Distribution of the composite score dif-
fered significantly by stage (p = 0.0043). A higher proportion 
of patients with stage I NSCLC had the maximum possible 
score of 12 (77%) compared with stage II (18%) and stage III 
(57%) (p = 0.0001). On pair-wise comparison, patients with 
stage I NSCLC had a significantly higher proportion of com-
posite scores of 12 as compared with stage II (p = 0.0009), 
but not stage III (p = 1.0). The proportion of patients with a 
composite score of 12 were not significantly different between 
patients with stage II and III (p = 0.16). In the 26 patients 
who had data for both the primary tumor and corresponding 
metastatic lymph node, MUC4 expression was higher in the 
primary tumor compared with the metastasis (p = 0.05). The 
effect of MUC4 expression on survival was analyzed in 29 
patients with survival data. Of these, 16 had a composite score 
FIGURE 5.  Up-regulation/activation of various metastasis-promoting signaling molecules and transcription factors with 
decreased MUC4 expression. Up-regulation of N-cadherin and down-regulation of E-cadherin/CK18 in cells lacking MUC4 (i.e., 
H292-ShMUC4 and A549-Vector) observed by confocal analyses (A) and Western blot (B). Increased phosphorylation of FAK 
(Y925 and Y577) was observed in MUC4 knockdown H292 cells in comparison with vector control cells (C).
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of 12, whereas 13 had a score less than 12. Patients with a 
score less than 12 had significantly worse survival than those 
with a score of 12 (p = 0.042) (Fig. 7).
DISCUSSION
The objective of this study was to investigate the role of 
MUC4 on lung cancer cell proliferation and metastatic pheno-
type. The results demonstrate that MUC4 expression inhibits 
lung cancer cell proliferation and metastatic behavior in two 
separate lung cancer cell lines. These results seem to be con-
firmed by data from clinical specimens. Although H292 is an 
epithelial-type primary cancer cell line, A549 is a mesenchy-
mal-type cell line.22 MUC4 down-regulation seems to trans-
form epithelial to mesenchymal phenotype, whereas MUC4 
expression reverses the phenotype in A549-MUC4 cells. To 
the best of our knowledge, this is the first investigation of the 
role of MUC4 as a tumor suppressor in NSCLC.
MUC4 has been implicated for oncogenic function in 
many cancers including pancreas,1 ovarian,23 and breast.24 In 
this study, we have seen that expression of MUC4 inhibits 
lung cancer cell proliferation by down-regulating the cell cycle 
proteins such as Cyclin A and Cyclin D1. Cyclin-dependent 
kinase inhibitors p21 and p27 were strongly up-regulated in 
MUC4-expressing lung cancer cells, suggesting that MUC4 
plays a tumor-suppressor role in lung cancer by altering cell 
cycle regulator proteins. The decreased expression of GSK3β 
and phosphorylation of Akt in MUC4-expressing lung cancer 
cells suggests that expression of MUC4 suppresses lung can-
cer cell proliferation through regulation of GSK3β and Akt 
activation. A previous study demonstrated that Akt activation 
regulates cancer cell proliferation by proteasomal targeting of 
p21Cip1 and p27Kip1 and that loss of GSK3β stabilizes G1-phase 
cell cycle proteins (Cyclin D and E) and transcription factors 
c-Jun and c-Myc during cancer cell progression.19
Tumor-suppressor p53 is mutated in 50% of patients with 
lung cancer,25 which suggests that in a large subsection of lung 
cancer cases, the function of p53 is compromised. Recently, 
high levels of wild-type P53 expression in melanoma were 
shown to be transcriptionally inactive.26 Our results suggest 
that MUC4 induces p53, resulting in G2/M arrest as evident 
from the higher percent of G2/M cells in MUC4-expressing 
lung cancer cells. Data from this study suggest that MUC4 
regulates p53 function as part of its tumor-suppressor role. 
Similarly, we have seen a decreased growth rate in MUC4-
expressing lung cancer cells. The positive regulation of p53 
expression and decreased growth rate of lung cancer cells by 
MUC4 could be of therapeutic importance in the future.
FIGURE 6.  Expression of MUC4 in different stages 
of lung cancer tissues and nonneoplastic lung tis-
sues. Immunohistochemical analysis was carried 
out with anti-MUC4 antibody (8G7) on lung cancer 
tissue sections from a commercial array. The descrip-
tion of the 100 tissue spots examined was as follows: 
cancer stage I (n = 29), II (n = 15), III (n = 21), and 
IV (n = 10) and nonmalignant lung tissues (n = 25). 
Decreasing immunoreactivity for MUC4 in increas-
ing grades of lung cancer tissues was observed with 
statistical significance (p = 0.0093).
FIGURE 7.  Comparison of overall survival in patients with 
lung cancer based on MUC4 expression: Patients with a com-
posite score of less than 12 by immunohistochemistry had a 
worse overall survival (p = 0.042).
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On studying the effect of MUC4 expression on the met-
astatic potential of lung cancer cells, we found that the most 
significant effect of MUC4 was on cell migration and inva-
sion, with a significant decrease in MUC4-expressing cells 
and a corresponding increase in MUC4-nonexpressing lung 
cancer cells. These results clearly suggest that expression of 
MUC4 significantly inhibits the invasive and motile properties 
of lung cancer cells. Furthermore, evaluation of the epithelial 
and mesenchymal marker profile indicates that N-cadherin 
expression was up-regulated in MUC4 knockdown H292 
cells along with a corresponding decrease in expression of 
E-cadherin. In MUC4-overexpressing A549 cells, the epithe-
lial marker CK-18 expression was increased and N-cadherin 
was decreased compared with MUC4-nonexpressing con-
trol cells. These results suggest that expression of MUC4 
suppresses N-cadherin expression, thereby resulting in 
decreased invasive and motile properties of lung cancer cells. 
Furthermore, activated FAK is increased in MUC4 knock-
down cells, which showed highly invasive and motile prop-
erties. These results suggest that increased motility of lung 
cancer cells may be due to the activation of FAK-signaling 
pathway in the absence of MUC4.
In epithelial malignancies, altered mucin expression 
is significantly correlated with tumor progression. In tissues 
lacking MUC4 expression such as pancreas, breast, and ovary, 
MUC4 expression is observed after the onset of cancer and 
correlates with cancer progression and confers a poor progno-
sis.23,24,27 In contrast, MUC4 is the first mucin to be expressed 
in the lung, as early as 6.5 weeks of gestation in the embryonic 
foregut before organogenesis and cytodifferentiation in the 
primitive lung bud.12 MUC4 expression is retained to adult-
hood, when it is expressed strongly in the upper airways and 
moderately in bronchioles.
In our studies with the commercial TMA, we found 
a significant decrease in MUC4 expression with advanced 
stages of the disease with metastatic lesions expressing the 
least MUC4. However, we could not evaluate MUC4 expres-
sion at the inception of tumorigenesis, as our normal tissue 
specimens comprised mainly of lower bronchioles and ter-
minal air sacs where MUC4 is virtually absent. Of note, the 
cancer adjacent normal tissue also lacked MUC4 expression.
Similarly, staining patterns from the patient samples 
show that a significantly higher proportion of patients with 
stage I disease had a composite score of 12 (maximum inten-
sity and extent of staining). Moreover, patients with a compos-
ite score of 12 had a better survival as compared with those 
with a score of less than 12. Unfortunately, due to an inad-
equate number of samples, we were unable to adjust for stage, 
but the results seem to suggest that at the very least, MUC4 
does not adversely affect lung cancer outcomes. This is also 
borne out by our finding that in patients with paired samples, 
the primary tumor had a greater composite MUC4 score than 
the corresponding metastatic lymph node. This would suggest 
loss of MUC4 expression as the lung cancer cells metastasize 
out of their primary site. Another hypothesis would be that the 
presence of MUC4 prevents spread of the tumor cells outside 
the primary.
Previous studies lack a consensus on the significance of 
MUC4 expression on lung cancer progression. Elevated levels 
of MUC4 mRNA were associated with poor prognosis.16 On 
the contrary, other studies have shown that MUC4 expression 
was associated with better survival and that reduced expres-
sion was found in all non–small-cell carcinomas.28 It is hoped 
that our results based both on in vitro studies and patient 
samples will put to rest the controversy regarding the role of 
MUC4 in NSCLC.
In conclusion, we found a significant increase of meta-
static/proliferative stimuli in the absence of MUC4 expres-
sion, suggesting a tumor-suppressor role of MUC4 (Fig. 8). 
However, this needs to be established in a wider sample of 
tissues to determine if this novel function of MUC4 is tissue 
specific or mutation specific.
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